Pythia Labs launches with Pythia-1, AI-designed full-length antibodies against hard targets

Pythia Labs announced its launch on October 27, 2026 alongside a bioRxiv preprint introducing Pythia-1, an all-atom generative model that designed full-length human IgGs across 22 targets, including GPCR agonist and antagonist antibodies. The company shares the lead antibody sequences; results are the company's own and weights or code are not stated. Business Wire release.